Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Pontremoli

Showing results (41-50 of 211) with videos related to

Pageof 22
Sort By:
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|October 28, 2021
Possible Advantages Deriving from Patiromer Use in Hypertensive Patients Made Hyperkalemic by Renin-Angiotensin-Aldosterone Blocking AgentsClaudio Borghi, Claudio Ferri, Roberto Pontremoli, et al.
European Journal of Internal Medicine|March 7, 2026
Optimizing cardiorenal protection in HFrEF: from pharmacological mechanisms to clinical implementation. Author's replyElisa Russo, Emilio Venturelli, Giovanna Leoncini, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|May 26, 2015
[Hyperuricemia, diabetes and hypertension]Francesca Viazzi, Barbara Bonino, Elena Ratto, et al.
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|August 2, 2014
Early renal abnormalities as an indicator of cardiovascular risk in type 2 diabetesFrancesca Viazzi, Barbara Bonino, Elena Ratto, et al.
International Journal of Molecular Sciences|April 30, 2021
SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical BenefitsGiovanna Leoncini, Elisa Russo, Elisabetta Bussalino, et al.
Drug Safety|May 3, 2020
Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical StudiesArrigo F G Cicero, Roberto Pontremoli, Federica Fogacci, et al.
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|March 4, 2026
Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill CombinationMaria Lorenza Muiesan, Aldo Pietro Maggioni, Roberto Pontremoli, et al.
Current Pharmaceutical Design|January 31, 2012
RAAS inhibition and renal protectionGiovanna Leoncini, Leoncini Giovanna, Francesca Viazzi, et al.
Journal of Nephrology|April 24, 2014
Increased urine semaphorin-3A is associated with renal damage in hypertensive patients with chronic kidney disease: a nested case-control studyFrancesca Viazzi, Ganesan Ramesh, Calpurnia Jayakumar, et al.
International Journal of Molecular Sciences|July 1, 2020
Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric AgeElisa Russo, Giovanna Leoncini, Pasquale Esposito, et al.
Pageof 22

Showing results (41-50 of 211) with videos related to

Sort By:
Pageof 22
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|October 28, 2021
Possible Advantages Deriving from Patiromer Use in Hypertensive Patients Made Hyperkalemic by Renin-Angiotensin-Aldosterone Blocking AgentsClaudio Borghi, Claudio Ferri, Roberto Pontremoli, et al.
European Journal of Internal Medicine|March 7, 2026
Optimizing cardiorenal protection in HFrEF: from pharmacological mechanisms to clinical implementation. Author's replyElisa Russo, Emilio Venturelli, Giovanna Leoncini, et al.
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|May 26, 2015
[Hyperuricemia, diabetes and hypertension]Francesca Viazzi, Barbara Bonino, Elena Ratto, et al.
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|August 2, 2014
Early renal abnormalities as an indicator of cardiovascular risk in type 2 diabetesFrancesca Viazzi, Barbara Bonino, Elena Ratto, et al.
International Journal of Molecular Sciences|April 30, 2021
SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical BenefitsGiovanna Leoncini, Elisa Russo, Elisabetta Bussalino, et al.
Drug Safety|May 3, 2020
Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical StudiesArrigo F G Cicero, Roberto Pontremoli, Federica Fogacci, et al.
High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension|March 4, 2026
Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill CombinationMaria Lorenza Muiesan, Aldo Pietro Maggioni, Roberto Pontremoli, et al.
Current Pharmaceutical Design|January 31, 2012
RAAS inhibition and renal protectionGiovanna Leoncini, Leoncini Giovanna, Francesca Viazzi, et al.
Journal of Nephrology|April 24, 2014
Increased urine semaphorin-3A is associated with renal damage in hypertensive patients with chronic kidney disease: a nested case-control studyFrancesca Viazzi, Ganesan Ramesh, Calpurnia Jayakumar, et al.
International Journal of Molecular Sciences|July 1, 2020
Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric AgeElisa Russo, Giovanna Leoncini, Pasquale Esposito, et al.
Pageof 22